Clinical management of pregnant women with the risk of pre-eclampsia developing.
DOI:
https://doi.org/10.26641/2307-0404.2015.1.40305Keywords:
pregnancy, pre-eclampsia, gene polymorphism, hemostasis, antiphospholipid antibodies, prognosis, probability, risk group, tacticsAbstract
Hypertensive disorders in pregnancy remain important problem of modern obstetrics, their frequency being 2-8% with no tendency of decreasing. To identify pregnant women with high risk and to conduct preventive treatment is very important for the practitioner. The aim of the study was to develop and justify differential management of pregnants depending on the risk of preeclampsia. 131 pregnant women in I trimester were tested to determine the risk of hypertensive disorders. Prediction model allows to identify pregnant women with risk of hypertensive disorders according to the results of testing thrombophilia genes (presence of 455G → A polymorphism in the gene for fibrinogen β and 4G/5G in gene of plasminogen activator inhibitor - type 1), the level of antibodies to β2 glycoprotein-1, the level of D-dimer and the value of atherogenicity coefficient. Pregnant women with high risk of hypertensive disorders, received prophylactic treatment complex. This complex included antiplatelet therapy, correction of hyperhomocysteinemia and hypercholesterolemia levels. Etio-pathogenic concept of prediction and prevention of pre-eclampsia associated with thrombophilia was proposed. The proposed scheme of preventive treatment allowed to normalize blood clotting parameters, lipid metabolism, to reduce the number of thrombophilia markers. The necessity of early and long-term administration of prophylactic complex was proved. This management prevents endothelial damage and development of pathological range of pre-eclampsia. The results of prophylactic treatment were the reduction of preeclampsia cases by 6,5 times (p < 0.05), number of complicated deliveries by 3 times (p <0.05), number of preterm birth by 6,57 times (p <0.05), cases of growth retardation by 9,8 times (p = 0.003), increase of newborns’ weight by 1,24 times (p = 0.02).References
Loskutova ТО. [Effectiveness of prognosis of pre¬eclampsia in pregnancy]. Medichni perspectivy. 2014;XIX (1):101-7. Ukrainian 2. Baranov VS, Ivashchenko TE, Glotov AS. [De¬termination of genetic predisposition to certain diseases common in pregnancy: guidelines]. SPb.: «Iz-vo N-L». 2009;68. Russian. 3. [On approval of clinical protocols for obstetric and gynecological care: Order of 31.12.2004 № 676]. Mіnіsterstvo okhoroni zdorov’ya Ukraїni. K; 2004. Ukrainian. 4. Makatsariya AD, Bitsadze VO, Baymuradova SM, Perederyeva EB. [Prevention of recurrent pregnancy complications in terms of thrombophilia. Guide for Physicians]. M.: Triada Kh. 2008;152. Russian. 5. Turchin VN. [Probability theory and mathe¬matical statistics. Basic concepts, examples and tasks]. Dnipropetovsk: IMA-PRESS. 2012;576. Russian. 6. Gordon Guyatt H, Elie A, Crowther M. Anti¬throm¬botic Therapy and Prevention of Thrombosis, 9th edition: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2)(suppl.):7S-47S. 7. Chappell LC, Seed P, Enye S. Clinical and geographical variation in prophylactic and therapeutic treatments for pre-eclampsia in the UK. BJOG. 2010;117(6):695-700. 8. Woodham PC, Boggess KA, Gardner MO. Rou¬tine antenatal thrombophilia screening in high-risk pregnancies: a decision analysis. Am. J. Perinatol. 2011;28(6):495-500. 9. Milne F, Redman C, Walker J. The pre-eclampsia community guideline (PRECOG): how to screen for and detect onset of preeclampsia in the community. BMJ. 2005;330:576–80. 10. WHO recommendations for Prevention and treatment of pre-eclampsia and eclampsia. Geneva. Swit¬zerland: World Health Organization. 2011;38.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2017 Medical Perspectives
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Submitting manuscript to the journal "Medicni perspektivi" the author(s) agree with transferring copyright from the author(s) to publisher (including photos, figures, tables, etc.) editor, reproducing materials of the manuscript in the journal, Internet, translation into other languages, export and import of the issue with the author’s article, spreading without limitation of their period of validity both on the territory of Ukraine and other countries. This and other mutual duties of the author and all co-authors separately and editorial board are secured by written agreement by special form to use the article, the sample of which is presented on the site.
Author signs a written agreement and sends it to Editorial Board simultaneously with submission of the manuscript.